Trading Signals: IOVA Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 27, 2023)(Iovance Biotherapeutics Inc)
| IOVA latest price $7.4250 (4.28%) ($7.4250 - $7.4250) on Fri. Mar. 3, 2023. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.57% (three month average) | RSI | 51 | Latest Price | $7.4250(4.28%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | IOVA advances 1.1% a day on average for past five trading days. | Weekly Trend | IOVA advances 0.3% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support IOVA advance at 0% a week (0% probability) XBI(49%) IBB(36%) ACES(28%) IWC(28%) ARKG(26%) | Factors Impacting IOVA price | IOVA will decline at least -2.285% in a week (0% probabilities). VIXM(-12%) BND(-12%) XLP(-11%) UUP(-10%) EDOC(-10%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -2.285% (StdDev 4.57%) | Hourly BBV | 1.6 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $7.26(2.27%) | 10 Day Moving Average | $7.21(2.98%) | 20 Day Moving Average | $7.38(0.61%) | To recent high | -9.9% | To recent low | 32.4% | Market Cap | $1.087b | | | | Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA. |